Manufacturing & Packaging

CDMO’s Taoyuan City plant is set to provide customers with products ranging from emulsions to gels.

CDMO’s Turku addition will span over 69,000 square feet and support the production of ATMPs.

Sterile injectable plant—struck by tornado—is currently being assessed.

The 19,500 square-foot warehouse will support API manufacturing activities, all the way through commercialization.

The debut will be the CDMO’s first fully automated sterile injectable manufacturing line at the Wuxi, China site.

Report reiterates CDMO’s commitment to net-zero emissions.

Goal of the deal is to boost the production of oral dosage forms.

The 50,000 square-foot facility will feature 10 new manufacturing sites with commercial capabilities.

Platform is expected to streamline the label management process.

Initiative to support developing manufacturers launch new products.

According to a recent TMR study, there is an expected CAGR increase of 5.6%.

The 200,000 square-foot manufacturing plant—coming early next year—is expected to help boost capacity of pharma packaging materials.

The series’ marking heads help deliver codes to support both product traceability and anti-counterfeiting efforts.

Expansion expected to create additional production capacity, company says.

Changes to 3PL’s facility feature newly-converted controlled room temperature pallets.

CDMO’s new facility is expected to be operational by April 2025.

The accreditations—granted to the company’s sites in the US, LATAM, and Canada—are given for compliance with specific pharma manufacturer guidelines.

Decision is anticipated to boost operational efficiencies for the CDMO.

Company is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

Company’s latest report reveals future plans, powered by efforts to divert more of its air shipments to sea.

New fill-finish plant strengthens nation’s reputation as an APAC biomedical hub.

Document reveals that 20 of 28 of participating Big Pharma manufacturers saw their DIO increase by an average of 5%, suggesting that large amounts of inventory do not necessarily offer protection from running low on medication.

The treatments span various therapeutic areas, from antibiotic to oncology.

New capability will support manufacturing of commercial-stage therapies to help combat cancers and genetic diseases.

Roundtable drills down on ways the two sectors can come together to reduce carbon emissions.

Real-time location monitoring solution allows increased visibility into the precise location of shipments in transit globally.

CDMO’s fill-finish line offers batch capacity of over 200,000 syringes.

Company will also financially commit $15 million for those pursuing pharma manufacturing careers.

Merger with pharmacovigilance service provider helps company expands its end-to-end solutions in the region.